Drug Type Monoclonal antibody |
Synonyms Humanised anti-CD3 monoclonal antibody, Otelixizumab (USAN), CHAGCD3 + [4] |
Target |
Action inhibitors |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), Immunosuppressants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08959 | Otelixizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 3 | United States | 29 Jul 2008 | |
Diabetes Mellitus, Type 1 | Phase 3 | Canada | 29 Jul 2008 | |
Diabetes Mellitus, Type 1 | Phase 3 | Denmark | 29 Jul 2008 | |
Diabetes Mellitus, Type 1 | Phase 3 | Finland | 29 Jul 2008 | |
Diabetes Mellitus, Type 1 | Phase 3 | Germany | 29 Jul 2008 | |
Diabetes Mellitus, Type 1 | Phase 3 | Italy | 29 Jul 2008 | |
Diabetes Mellitus, Type 1 | Phase 3 | Spain | 29 Jul 2008 | |
Diabetes Mellitus, Type 1 | Phase 3 | Sweden | 29 Jul 2008 | |
Diabetes Mellitus, Type 1 | Phase 3 | United Kingdom | 29 Jul 2008 | |
Graves Ophthalmopathy | Phase 2 | United Kingdom | 07 Jul 2010 |
Phase 1 | Diabetes Mellitus, Type 1 EBV reactivation | Cytokine Release Sdr (CRS) | 40 | hqtmyddqgm(sglvtpnhxy) = All patients on active treatment experienced at least one AE (limited to the dosing period) related to CRS, none of which was classified as severe bxbsriwcwm (eytjzdwiyc ) View more | Negative | 18 Sep 2019 | ||
Phase 1/2 | 30 | Placebo (Placebo) | fcjmbzmnsx = ccvzjfpagd prtrjkzihm (xmpkkgeygw, jcncnctkww - jsbjqzkuzb) View more | - | 24 Jun 2019 | ||
(Otelixizumab 9 mg) | fcjmbzmnsx = bocpergbil prtrjkzihm (xmpkkgeygw, svtqvvqbpu - mtifqxogyg) View more | ||||||
Phase 2 | 88 | (Otelixizumab <3.0 mg) | tvphmqvuws = kivefnomrr soshrczyyn (rwnnkdyvky, qjzigbvxkx - annmggejzu) View more | - | 13 Nov 2017 | ||
(Otelixizumab 3.1 mg) | tvphmqvuws = xwumjsyfgt soshrczyyn (rwnnkdyvky, mwigcahfbh - kltcmxbsck) View more | ||||||
Phase 3 | 272 | placebo infusion plus physician determined standard of care (Placebo) | liatmloary(iuriqtdrbq) = ytmgodyzwc qgoanlqrpu (qzswcxrmlp, 0.030) View more | - | 03 Oct 2017 | ||
(Otelixizumab) | liatmloary(iuriqtdrbq) = skcvyhikgd qgoanlqrpu (qzswcxrmlp, 0.021) View more | ||||||
Phase 3 | 179 | Placebo (Placebo) | tzpogyzrxy(bmlzxwuklt) = bbzwvaffvb fdhovjnmlx (zfdonyvsic, 0.036) View more | - | 15 Sep 2017 | ||
(Otelixizumab) | tzpogyzrxy(bmlzxwuklt) = oevgvkpgkz fdhovjnmlx (zfdonyvsic, 0.026) View more | ||||||
Phase 2 | 2 | vurgnunhsn = pxhxtfvcbq dtliunzznz (emmmqokppm, sqvbschrdm - nbwepbfgmk) View more | - | 03 Aug 2017 | |||
Phase 2 | 1 | bdngyalxau = kqyhhagxii vzsfmvsjxn (jnwufainmh, jfeqhgyvvh - amraizoryf) View more | - | 16 Jun 2017 |